Late side effects of cancer therapy

COŞKUN, Uğur; BENEKLİ, Mustafa; BÜYÜKBERBER, Süleyman; DEMIRCI, UMUT

Late side effects of cancer therapy

Umut DEMİRCİ, (Gazi Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, Ankara, Türkiye)

Mustafa BENEKLİ, (Gazi Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, Ankara, Türkiye)

Süleyman BÜYÜKBERBER, (Gazi Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, Ankara, Türkiye)

Uğur COŞKUN (Gazi Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, Ankara, Türkiye)

Uluslararası Hematoloji-Onkoloji Dergisi

4 2

Yıl: 2010 Cilt: 20 Sayı: 4 Sayfa Aralığı: 250 - 261 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Late side effects of cancer therapy

Öz:

Kanser tedavisinde yeni ajanlar ve eş zamanlı tedaviler ile ileri evrelerde dahi hastalık kontrol edilmekte ve kür şansı artmaktadır. Geç yan etkiler tedavi sonrası geçmeyen veya tedavi tamamlanmasından sonra ortaya çıkan etkiler olarak tanımlanır. Günümüzde tedavi sonrası uzun dönem kür elde edilen hasta sayısının artması ile çok sayıda geç yan etki daha fazla dikkat çekmektedir. Bu hastalar multidisipliner bir ekip tarafından takip edilmelidir. Hastalara ömür boyu sürecek tarama ve erken tanı programları uygulanmalıdır. Bu hızla büyüyen grupta, kanser ve kanser tedavisinin takibi ve geç yan etkilerini objektif olarak ortaya koyan kılavuzlara ihtiyacımız vardır. Böylelikle kanser tedavisi komplikasyonlarını erken tespit edebilir, erken tedavi ile sekel oluşumunu engelleyerek hastaların hayat kalitesini ve uzun dönem sağkalımlarını olumlu yönde etkileyebiliriz.

Anahtar Kelime:

Konular: Onkoloji

Kanser tedavisinin geç yan etkileri

Öz:

In cancer treatment, control of advanced stage disease and cure chances are increased after the introduction of new agents and combined treatments. Late side effects can be described as the effects that have not been recovering after treatment or developing after completion of treatment. Nowadays, patients who achieve long term cure are increasing therefore, thus many late side effects are more evident. These patients should be evaluated by a multidisciplinary team. Detection and early diagnosis programs should be performed to cancer survivors lifelong. In this rapidly growing population, we need guidelines that follow and describe late side effects objectively about cancer and cancer treatment. In this way, complications of cancer treatment can be detected earlier. By preventing sequelae formation with early treatment, quality of life and long term survival can be improved.

Anahtar Kelime:

Konular: Onkoloji

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. van Dalen EC, van der Pal HJ, Bakker PJ, et al. Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: Asystematic review. Eur J Cancer 40: 643-652, 2004.
2. Carver JR, Shapiro CL, Ng A, et al. ASCO Cancer Survivorship Expert Panel. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 25: 3991-4008, 2007.
3. Ries LA, Percy CL, Berin GR. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program, 1975–1995. In: SEER pediatric monograph. Ries LA, Smith M, Gurray JA et al. NIH publication no: 99-464+9, MD National Cancer Institute; Bethesda, 1999, 1-5.
4. Hudson MM, Mertens AC, Yasui Y, et al. Health status of adult long-term survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. JAMA 290: 1583-1592, 2003.
5. Oeffinger KC, Eshelman DA, Tomlinson GE, et al. Grading of late effects in young adult survivors of childhood cancer followed in an ambulatory adult setting. Cancer 88: 1687-1695, 2000.
6. Oeffinger KC, Hudson MM. Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors CA Cancer J Clin 54: 208-236, 2004.
7. Stevens MC, Mahler H, Parkes. The health status of adult survivors of cancer childhood. Eur J Cancer 34: 694-698, 1998.
8. Dickerman JD. The late effects of childhood cancer therapy. Pediatrics 119: 554-568, 2007.
9. Atasoy BM, Unsal DK, Dincbas FO, et al. The results of questionnaire on assessing and reporting of side effects in Turkey: “Turkish Oncology Group (TOG) Early- Late Side Effects Working Party” study. Turkish Journal of Cancer 22: 13-19, 2007.
10. Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 22: 4979-4990, 2004.
11. Ganz PA, Hussey MA, Moinpour CM, et al. Late Cardiac Effects of Adjuvant Chemotherapy in Breast Cancer Survivors Treated on Southwest Oncology Group Protocol s8897. J Clin Oncol 26: 1223-30, 2008.
12. Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 20: 3484-3494, 2008.
13. Hudson MM, Tyc VL, Srivastava DK, et al. Multi-component behavioral intervention to promote health protective behaviors in childhood cancer survivors: The protect study. Med Pediatr Oncol 39: 2-11, 2002.
14. Benekli M, Kars A, Guler N. Mitoxantrone induced bradycardia. Ann Intern Med 126: 409, 1997. 15. Gianni L, Herman EH, Lipshultz SE, et al. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 26: 3777-3784, 2008.
16. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 94: 525-533, 2008.
17. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324: 808-815, 1991.
18. de Graaf H, Dolsma WW, Willemse PH, et al. Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer. Br J Cancer 76: 943-945, 1997.
19. Mattioli R, Lippe P, Massacesi C, et al. Long-survival in responding patients with metastatic breast cancer treated with doxorubicin-docetaxel combination. A multicentre phase II trial. Anticancer Res 2004;24:3257- 3261.
20. Von Hoff DD, Layard M. Risk factors for development of daunorubicin cardiotoxicity. Cancer Treat Rep 65: 19-23, 1981.
21. Early Breast Cancer Trialists’ Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 355: 1757-1770, 2000.
22. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin- treated survivors of childhood cancer. J Clin Oncol 20: 4517-4522, 2002.
23. Nuver J, Smit AJ, Sleijfer DT, et al. Left ventricular and cardiac autonomic function in survivors of testicular cancer. Eur J Clin Invest 35: 99-103, 2005.
24. Shan K, Lincoff AM, Young JB. Anthracycline induced cardiotoxicity. Ann Intern Med 125: 47-58, 1996.
25. Ganz WI, Sridhar KS, Ganz SS, et al. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology 53: 461-470, 1996.
26. Tripathy D, Seidman A, Keefe D, et al. Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 5: 293-298, 2004.
27. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 23: 7820-7826, 2005.
28. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breastcancer: NSABP B-31. J Clin Oncol 23: 7811-7819, 2005.
29. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354: 809- 820, 2006.
30. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20: 1215-1221, 2002.
31. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
32. Theodoulou M, Seidman AD. Cardiac effects of adjuvant therapy for early breast cancer. Semin Oncol 30: 730-739, 2003.
33. Heidenreich PA, Hancock SL, Lee BK, et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 42: 743-749, 2003.
34. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351: 145-153, 2004.
35. Cheng SW, Ting AC, Lam LK, et al. Carotid stenosis after radiotherapy for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 126: 517-521, 2000.
36. Haynes JC, Machtay M, Weber RS, et al. Relative risk of stroke in head and neck carcinoma patients treated with external cervical irradiation. Laryngoscope 112: 1883-1887, 2002.
37. Villani F, De Maria P, Bonfante V, et al. Late pulmonary toxicity after treatment for Hodgkin’s disease. Anticancer Res 17: 4739-4742, 1997.
38. Aisner J, Goutsou M, Maurer LH, et al. Intensive combination chemotherapy, concurrent chest irradiation, and warfarin for the treatment of limited-disease smallcell lung cancer: A Cancer and Leukemia Group B pilot study. J Clin Oncol 10: 1230-1236, 1992.
39. Sleijfer S. Bleomycin-induced pneumonitis. Chest 120: 617-624, 2001.
40. Read WL, Mortimer JE, Picus J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer 94: 847-853, 2002.
41. Granena A, Carreras E, Rozman C, et al. Interstitial pneumonitis after BMT: 15 years experience in a single institution. Bone Marrow Transplant 11: 453-458, 1993.
42. McDonald S, Rubin P, Phillips TL, et al. Injury to the lung from cancer therapy: Clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys 31: 1187-1203, 1995.
43. Wilczynski SW, Erasmus JJ, Petros WP, et al. Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer. Am J Respir Crit Care Med 157: 565-573, 1998.
44. Gurney JG, Kadan-Lottick NS, Packer RJ, et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer 97: 663-673, 2003.
45. Liversey EA, Hindmarsh PC, Brook CG, et al. Endocrine disorders following treatment of childhood brain tumours. Br J Cancer 61: 622-625, 1990.
46. Nandagopal R, Laverdiere C, Mulrooney D, et al. Endocrine late effects of childhood cancer therapy: a report from the children’s oncology group. Horm Res 69: 65-74, 2008.
47. Lannering B, Marky I, Mellander L, et al. Growth hormone secretion and response to growth hormone therapy after treatment for brain tumour. Acta Paediatr Scan 343: 146-151, 1998.
48. Hancock SL, Cox RS, McDougall IR, et al. Thyroid diseases after treatment of Hodgkin’s disease. N Engl J Med 325: 599-605, 1991.
49. Brennan BM, Rahim A, Mackei EM, et al. Growth hormone status in adults treated for acute lymphoblastic leukemia in childhood. Clin Endocrinol (Oxf) 48: 777- 783, 1998.
50. Swerdlow AJ, Reddinguis RE, Higgins CD, et al. Growth hormone treatment of children with brain tumours and risk of tumour recurrence. J Clin Endocrinol Metab 85: 4444-4449, 2002.
51. Clayton PE, Shalet SM, Gattameni HR, et al. Does growth hormone cause relaps of brain tumours? Lancet 1: 711-713, 1987.
52. Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of hodgkin’s disease. N Eng J Med 325: 599-605, 1991.
53. Sklar C, Whitton J, Mertens A, et al. Abnormalities of the thyroid survivors of Hodgkin’s disease: data from the Childhood Cancer Survivor Study. Journal of Clinical Endocrinology and Metabolism 85: 3227-3232, 2000.
54. Rao SD, Frame B, Miller MJ, et al. Hyperparathyroididm following head and neck irradiation. Cancer 140: 205-207, 1979.
55. Sklar C, Whitton J, Mertens A, et al. Changes in body mass index and prevelance of overweight in survivors of childhood acute lymphoblastic leukemia: role of cranial irradiation. Med Pediatr Oncol 127: 91-95, 2000.
56. Talvensaari KK, Lanning M, Tapanainen P, et al. Long term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. J Clin Endocrinol Metab 81: 3051-3055, 1996.
57. Santoro A, Bonadonna G, Valagussa P, et al. Lomgterm results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease: Superiorty of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5: 27-37, 1987.
58. Kinsella TJ, Trivette G, Rowland J, et al. Long-term follow- up of testicular fuction following radiation therapy for early stage Hodgkin’s disease. J Clin Oncol 7: 718- 724, 1989.
59. Narayan P, Lange PH, Fraley EE. Ejaculation and fertility after extended retroperitoneal lymph node dissection for testicular cancer. J Urol 127: 685-688, 1982.
60. Bryne J. Infertility and premature menapouse in childhood cancer survivors. Med Pediatr Oncol 33: 24-28, 1999.
61. Madan-Swain A, Brown RT. Cognitive and pshycosocial sequelae for children with acute lymphoblastic leukemia and their families. Clin Psychol Review 11: 267-294, 1991.
62. Packer RJ, Zimmerman RA, Bilanuik LT. Magnetic resonance imaging in the evoluation of treatmentreleated central nervous system damage. Cancer 58: 635-640, 1986.
63. Bottomley SJ, Kassner E. Late effects of childhood cancer therapy. J Pediatr Nurs 18: 126-133, 2003.
64. Recklitis CJ, Lockwood RA, Rothwell MA, et al. Suicidal ideation and attempts in adult survivors of childhood cancer. J Clin Oncol 24: 3852-3857, 2006.
65. Jones DP, Spunt SL, Gren D, et al. Renal late effects in patients treated for cancer in childhood: A report from the Children’s Oncology Group. Pediatr Blood Cancer 51: 724-731, 2008.
66. Erdlenbruch B, Nier M, Kern W, et al. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients. Eur J Clin Pharmacol 57: 393- 402, 2001.
67. Cohen EP, Robbins ME. Radiation nephropathy. Semin Nephrol 23: 486-499, 2003.
68. Rossi R, Kleta R, Ehrich JH. Renal involvement in children with malignancies. Pediatr Nephrol 13: 153- 162, 1999.
69. Smith GR, Thomas PR, Ritchey M, et al. Long-term renal function in patients with irradiated bilateral Wilms tumor. National Wilms’ Tumor Study Group. Am J Clin Oncol 21 :58-63, 1998.
70. Fairchild WV, Spence CR, Solomon HD, et al. The insidence of bladder cancer after cyclophosphomide therapy. J Urol 122: 163-164, 1991.
71. Perry MC. Hepatotoxicity of chemotherapeutic agents. Semin Oncol 9: 65-74, 1982.
72. Ducrey N, Nenadov-Beck M, Spahn B. Update of orbital rhabdomyosarcoma therapy in children. J Fr Ophtalmol 25: 298-302, 2002.
73. Hoover DL, Smith LE, Turner SJ, et al. Ophthalmic evaluation of survivors of acute lymphoblastic leukemia. Ophthalmology 95: 151-155, 1988.
74. Arikoski P, Kroger H, Riikonen P, et al. Disturbance in bone turnover in children with a malignancy at completion of chemotherapy. Med Pediatr Oncol 33: 455- 461, 1999.
75. Kaste SC, Jones-Wallace D, Rose SR et al. Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their devolepment. Leukemia 15: 728- 734, 2001.
76. Mattano LA Jr, Sather HN, Trigg ME, et al. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: A report from the Children's Cancer Group. J Clin Oncol 18: 3262-3272, 2000.
77. Kucukzeybek Y, Gourumlu G, Cengiz E, et al. Bisphosphonate (zoledronic acid) associated adverse events: single center experience. UHOD 20: 135-140, 2010.
78. Cecen E, Bolaman Z. Ikincil kanserler. UHOD 20: 190- 200, 2010.
79. Meadows AT, Friedman DL, Neglia JP, et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol 27: 2356-2362, 2009.
80. Cardous-Ubbink MC, Heinen RC, Bakker PJ, et al. Risk of second malignancies in long-term survivors of childhood cancer. Eur J Cancer 43: 351-362, 2007.
81. Ganz PA. Late effects of cancer and its treatment. Semin Oncol Nurs 17: 241-248, 2001.
82. Demirci U, Bugdayci F, Cakir A, et al. Bilateral breast cancer in a survivor of acute lymphoblastic leukemia: a case report. Med Oncol 27: 481-483, 2010.
83. Neglia JP, Maedows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 325: 1330-1336, 1991.
84. Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 278: 1262-1267, 1997.
85. Pui C-H, Riberio RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epidophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 325: 1682-1687, 1991.
86. Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 25: 1489-1497, 2007.
87. Mulvihill JJ, Myers MH, Connely RR, et al. Cancer in offspring of long-term survivors of childhood and adolescent cancer. Lancet 1: 813-817, 1987.

APA	DEMIRCI U, BENEKLİ M, BÜYÜKBERBER S, COŞKUN U (2010). Late side effects of cancer therapy. , 250 - 261.
Chicago	DEMIRCI UMUT,BENEKLİ Mustafa,BÜYÜKBERBER Süleyman,COŞKUN Uğur Late side effects of cancer therapy. (2010): 250 - 261.
MLA	DEMIRCI UMUT,BENEKLİ Mustafa,BÜYÜKBERBER Süleyman,COŞKUN Uğur Late side effects of cancer therapy. , 2010, ss.250 - 261.
AMA	DEMIRCI U,BENEKLİ M,BÜYÜKBERBER S,COŞKUN U Late side effects of cancer therapy. . 2010; 250 - 261.
Vancouver	DEMIRCI U,BENEKLİ M,BÜYÜKBERBER S,COŞKUN U Late side effects of cancer therapy. . 2010; 250 - 261.
IEEE	DEMIRCI U,BENEKLİ M,BÜYÜKBERBER S,COŞKUN U "Late side effects of cancer therapy." , ss.250 - 261, 2010.
ISNAD	DEMIRCI, UMUT vd. "Late side effects of cancer therapy". (2010), 250-261.

APA	DEMIRCI U, BENEKLİ M, BÜYÜKBERBER S, COŞKUN U (2010). Late side effects of cancer therapy. Uluslararası Hematoloji-Onkoloji Dergisi, 20(4), 250 - 261.
Chicago	DEMIRCI UMUT,BENEKLİ Mustafa,BÜYÜKBERBER Süleyman,COŞKUN Uğur Late side effects of cancer therapy. Uluslararası Hematoloji-Onkoloji Dergisi 20, no.4 (2010): 250 - 261.
MLA	DEMIRCI UMUT,BENEKLİ Mustafa,BÜYÜKBERBER Süleyman,COŞKUN Uğur Late side effects of cancer therapy. Uluslararası Hematoloji-Onkoloji Dergisi, vol.20, no.4, 2010, ss.250 - 261.
AMA	DEMIRCI U,BENEKLİ M,BÜYÜKBERBER S,COŞKUN U Late side effects of cancer therapy. Uluslararası Hematoloji-Onkoloji Dergisi. 2010; 20(4): 250 - 261.
Vancouver	DEMIRCI U,BENEKLİ M,BÜYÜKBERBER S,COŞKUN U Late side effects of cancer therapy. Uluslararası Hematoloji-Onkoloji Dergisi. 2010; 20(4): 250 - 261.
IEEE	DEMIRCI U,BENEKLİ M,BÜYÜKBERBER S,COŞKUN U "Late side effects of cancer therapy." Uluslararası Hematoloji-Onkoloji Dergisi, 20, ss.250 - 261, 2010.
ISNAD	DEMIRCI, UMUT vd. "Late side effects of cancer therapy". Uluslararası Hematoloji-Onkoloji Dergisi 20/4 (2010), 250-261.